Distinguished in Non-Small Cell Lung Cancer (NSCLC)

Dr. Karen L. Kelly

Hematology Oncology | Oncology | Hematology
2279 45th Street, 
Sacramento, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Non-Small Cell Lung Cancer (NSCLC)
2279 45th Street, 
Sacramento, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Karen Kelly is a Hematologist Oncology specialist and an Oncologist in Sacramento, California. Dr. Kelly is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 18 peer reviewed articles and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 9 articles and participated in 10 clinical trials in the study of Non-Small Cell Lung Cancer (NSCLC).

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in KS
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

2279 45th Street, Sacramento, CA 95817

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium
Study Phase: Phase 3
Phase 1 and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2-Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Brain Metastases
Phase 1 and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2-Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Brain Metastases
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2025
Intervention Type: Other, Drug, Radiation
Study Phase: Phase 1
Phase I Clinical Trial of M6620 (VX-970, Berzosertib) in Combination With the Topoisomerase I Inhibitor Irinotecan in Patients With Advanced Solid Tumors
Phase I Clinical Trial of M6620 (VX-970, Berzosertib) in Combination With the Topoisomerase I Inhibitor Irinotecan in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 24, 2025
Intervention Type: Procedure, Drug
Study Drugs: Berzosertib, Irinotecan Hydrochloride
Study Phase: Phase 1
A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
Enrollment Status: Active_not_recruiting
Publish Date: August 14, 2025
Intervention Type: Drug
Study Drug: Sotorasib
Study Phase: Phase 2
Phase I Study of TRC102 in Combination With Cisplatin and Pemetrexed in Patients With Advanced Solid Tumors / Phase II Study of TRC102 With Pemetrexed in Patients Refractory to Pemetrexed and Cisplatin or Carboplatin
Phase I Study of TRC102 in Combination With Cisplatin and Pemetrexed in Patients With Advanced Solid Tumors / Phase II Study of TRC102 With Pemetrexed in Patients Refractory to Pemetrexed and Cisplatin or Carboplatin
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2025
Intervention Type: Drug
Study Drugs: Cisplatin, Methoxyamine, Pemetrexed Disodium
Study Phase: Phase 1/Phase 2
Phase II Trial of Neoadjuvant and Adjuvant Capmatinib in Participants With Stages IB-IIIA, N2 and Selected IIIB (T3N2 or T4N2) NSCLC With MET Exon 14 Skipping Mutation or High MET Amplification (Geometry-N)
Phase II Trial of Neoadjuvant and Adjuvant Capmatinib in Participants With Stages IB-IIIA, N2 and Selected IIIB (T3N2 or T4N2) NSCLC With MET Exon 14 Skipping Mutation or High MET Amplification (Geometry-N)
Enrollment Status: Terminated
Publish Date: March 26, 2025
Intervention Type: Drug
Study Drug: Capmatinib
Study Phase: Phase 2
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Enrollment Status: Completed
Publish Date: February 13, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Enrollment Status: Completed
Publish Date: May 03, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase I Trial of an Immune Checkpoint Inhibitor Plus Stereotactic Ablative Radiotherapy in Patients With Inoperable Stage I Non-Small Cell Lung Cancer
A Phase I Trial of an Immune Checkpoint Inhibitor Plus Stereotactic Ablative Radiotherapy in Patients With Inoperable Stage I Non-Small Cell Lung Cancer
Enrollment Status: Unknown
Publish Date: July 03, 2023
Intervention Type: Drug, Radiation
Study Drug: Atezolizumab
Study Phase: Phase 1
Pilot Study of MPDL3280A Plus Stereotactic Ablative Radiotherapy (SAR) in Stage IV Non-small Cell Lung Cancer
Pilot Study of MPDL3280A Plus Stereotactic Ablative Radiotherapy (SAR) in Stage IV Non-small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: August 04, 2022
Intervention Type: Drug, Radiation
Study Drug: Anti-PD-L1 Monoclonal Antibody MPDL3280A
Study Phase: Phase 1
Phase I Study of the Combination of MLN8237 and Gemcitabine in Advanced Solid Tumors With Emphasis on Pancreatic Cancer
Phase I Study of the Combination of MLN8237 and Gemcitabine in Advanced Solid Tumors With Emphasis on Pancreatic Cancer
Enrollment Status: Completed
Publish Date: August 02, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1a/1b Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
A Phase 1a/1b Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
Enrollment Status: Completed
Publish Date: March 09, 2022
Intervention Type: Biological
Study Phase: Phase 1
Phase I Study of INC280 Plus Erlotinib in Patients With C-Met Expressing Non-Small Cell Lung Cancer
Phase I Study of INC280 Plus Erlotinib in Patients With C-Met Expressing Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: October 13, 2021
Intervention Type: Drug
Study Drugs: INC280, Erlotinib Hydrochloride
Study Phase: Phase 1
Phase II Trial of TG4010 Plus Nivolumab in Previously Treated Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)
Phase II Trial of TG4010 Plus Nivolumab in Previously Treated Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: October 13, 2021
Intervention Type: Biological
Study Drugs: TG4010, Nivolumab
Study Phase: Phase 2
A Phase 1b Study of LY2835219 in Combination With Multiple Single Agent Options for Patients With Stage IV NSCLC
A Phase 1b Study of LY2835219 in Combination With Multiple Single Agent Options for Patients With Stage IV NSCLC
Enrollment Status: Completed
Publish Date: September 11, 2020
Intervention Type: Drug
Study Phase: Phase 1
UCDCC#269: A Pilot Study of Interlesional IL-2 and Hypofractionated Radiotherapy in Patients With Metastatic Non-small Cell Lung Cancer Who Are Refractory to PD 1 / PD L1 Blockade.
UCDCC#269: A Pilot Study of Interlesional IL-2 and Hypofractionated Radiotherapy in Patients With Metastatic Non-small Cell Lung Cancer Who Are Refractory to PD 1 / PD L1 Blockade.
Enrollment Status: Completed
Publish Date: April 07, 2020
Intervention Type: Radiation, Drug
Study Phase: Early Phase 1
View 15 Less Clinical Trials

18 Total Publications

AI integrations with lung cancer screening: Considerations in developing AI in a public health setting.
AI integrations with lung cancer screening: Considerations in developing AI in a public health setting.
Journal: European journal of cancer (Oxford, England : 1990)
Published: January 10, 2025
Similar Doctors
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Jonathan W. Riess
Hematology Oncology | Hematology | Oncology
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Jonathan W. Riess
Hematology Oncology | Hematology | Oncology

Regents Of The Univ Of Ca

2315 Stockton Blvd, 
Sacramento, CA 
 (0.2 miles away)
916-734-2011
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jonathan Riess is a Hematologist Oncology specialist and a Hematologist in Sacramento, California. Dr. Riess is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Thymic Epithelial Tumor, Bone Marrow Aspiration, and Gastrostomy.

Distinguished in Non-Small Cell Lung Cancer (NSCLC)
Dr. Deepti Behl
Hematology Oncology | Oncology | Hematology
Distinguished in Non-Small Cell Lung Cancer (NSCLC)
Dr. Deepti Behl
Hematology Oncology | Oncology | Hematology

Sutter Valley Medical Foundation

2800 L St, 
Sacramento, CA 
 (1.5 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Deepti Behl is a Hematologist Oncology specialist and an Oncologist in Sacramento, California. Dr. Behl is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, and Small Cell Lung Cancer (SCLC).

Distinguished in Non-Small Cell Lung Cancer (NSCLC)
Dr. Primo N. Lara
Hematology Oncology | Hematology | Oncology
Distinguished in Non-Small Cell Lung Cancer (NSCLC)
Dr. Primo N. Lara
Hematology Oncology | Hematology | Oncology

Regents Of The Univ Of Ca

4501 X St, 
Sacramento, CA 
 (0.1 miles away)
916-734-5959
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Primo Lara is a Hematologist Oncology specialist and a Hematologist in Sacramento, California. Dr. Lara is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Familial Prostate Cancer, Nephrectomy, and Orchiectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kelly's expertise for a condition
ConditionClose
    View All 9 Distinguished Conditions
    View All 11 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile